NCT05009407

CD160 Expression in Corneal Vessels

CD160 Ans Corneal Graft: Expression in Corneal Vessels

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 43 (actual)
• Sponsor: CHU de Reims · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis

Detailed description

After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included. Routine general and eye examination including cornea photographs will be performed. During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.

Conditions

• Corneal Graft Rejection
• CD160
• Angiogenesis
• Lymphangiogenesis

Interventions

Type	Name	Description
BIOLOGICAL	Immunohistochemistry and clinical analyses on patients and corneas	Immunohistochemistry and clinical analyses on patients and corneas

Timeline

• Start date: 2021-04-21
• Primary completion: 2025-12-22
• Completion: 2025-12-22
• First posted: 2021-08-17
• Last updated: 2026-02-19

Locations

1 site across 1 country: France